Literature DB >> 19732775

Expanded extracolonic tumor spectrum in MUTYH-associated polyposis.

Stefanie Vogt1, Natalie Jones, Daria Christian, Christoph Engel, Maartje Nielsen, Astrid Kaufmann, Verena Steinke, Hans F Vasen, Peter Propping, Julian R Sampson, Frederik J Hes, Stefan Aretz.   

Abstract

BACKGROUND & AIMS: MUTYH-associated polyposis (MAP) is characterized by a lifetime risk of colorectal cancer of up to 100%. However, no systematic evaluation of extracolonic manifestations has been reported.
METHODS: A large cohort of MAP patients was recruited from a European multicenter study. Data were collected on 276 cases from 181 unrelated families. Information on extracolonic tumor spectrum and incidence were evaluated to determine cumulative lifetime risk, which was compared with that of the general population to obtain standardized incidence ratios (SIRs).
RESULTS: Duodenal polyposis occurred in 17% of cases; the relative risk (SIR) of duodenal cancer was 129 (95% confidence interval [CI]: 16-466), whereas the lifetime risk was 4%. The incidence of extraintestinal malignancies among cases was almost twice that of the general population (SIR: 1.9; 95% CI: 1.4-2.5), with a lifetime risk of 38%. We observed a significant increase in the incidence of ovarian, bladder, and skin cancers (SIR: 5.7, 7.2, and 2.8, respectively) and a trend of increased risk of breast cancer among cases. The median ages of onset of these 4 malignancies ranged from 51 to 61 years. In contrast to familial adenomatous polyposis, no desmoid tumors were observed, but sebaceous gland tumors, characteristic of the Muir-Torre variant of Lynch syndrome, occurred in 5 patients.
CONCLUSIONS: The relative risks for several extraintestinal malignancies increased in patients with MAP, but based on the spectrum of cancers (which overlaps with that of Lynch syndrome) and the relatively advanced age at onset, intensive surveillance measures other than frequent endoscopy are unlikely to be helpful to patients with MAP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732775     DOI: 10.1053/j.gastro.2009.08.052

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  86 in total

1.  MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer.

Authors:  María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  MUTYH associated polyposis coli: one common and one rare mutation.

Authors:  Heiko Ulrik De Schepper; Herbert Fierens; Piet-Hein Steger; Luc Colemont
Journal:  Dig Dis Sci       Date:  2012-03-09       Impact factor: 3.199

3.  Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis.

Authors:  Stefan Aretz; Frederik J Hes
Journal:  Eur J Hum Genet       Date:  2010-05-26       Impact factor: 4.246

4.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Authors:  Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

Review 5.  Hereditary Colorectal Cancer: Genetics and Screening.

Authors:  Lodewijk A A Brosens; G Johan A Offerhaus; Francis M Giardiello
Journal:  Surg Clin North Am       Date:  2015-06-16       Impact factor: 2.741

6.  French experts report on MUTYH-associated polyposis (MAP).

Authors:  Bruno Buecher; Catherine Bonaïti; Marie-Pierre Buisine; Chrystelle Colas; Jean-Christophe Saurin
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

7.  Frequency of pathogenic germline mutations in cancer susceptibility genes in breast cancer patients.

Authors:  Raman Preet Kaur; Gowhar Shafi; Raja Paramjeet Singh Benipal; Anjana Munshi
Journal:  Med Oncol       Date:  2018-04-26       Impact factor: 3.064

Review 8.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 9.  The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes.

Authors:  Stefan Aretz
Journal:  Dtsch Arztebl Int       Date:  2010-03-12       Impact factor: 5.594

10.  Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis.

Authors:  Erin G Sutcliffe; Amanda Bartenbaker Thompson; Amy R Stettner; Megan L Marshall; Maegan E Roberts; Lisa R Susswein; Ying Wang; Rachel T Klein; Kathleen S Hruska; Benjamin D Solomon
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.